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Abstract: A novel naturally-occurring bradykinin-related peptide (BRP) with an N-terminal extension,
named RVA-Thr6-Bradykinin (RVA-Thr6-BK), was here isolated and identified from the cutaneous
secretion of Odorrana hejiangensis (O. hejiangensis). Thereafter, in order to evaluate the difference in
myotropic actions, a leucine site-substitution variant from Amolops wuyiensis skin secretion, RVA-Leu1,
Thr6-BK, was chemically synthesized. Myotropic studies indicated that single-site arginine (R)
replacement by leucine (L) at position-4 from the N-terminus, altered the action of RVA-Thr6-BK
from an agonist to an antagonist of BK actions on rat ileum smooth muscle. Additionally, both BK
N-terminal extended derivatives (RVA-Thr6-BK and RVA-Leu1, Thr6-BK) exerted identical myotropic
actions to BK, such as increasing the frequency of contraction, contracting and relaxing the rat uterus,
bladder and artery preparations, respectively.
Keywords: bradykinin-related peptide (BRP); RVA-Thr6-BK; site-substitution variant; agonist;
antagonist; myotropic actions
Key Contribution: The full-length kininogen cDNA encoding skin kinins from O. hejiangensis was first
cloned and characterized. Position-4 from the N-terminus was found as the core site for converting
RVA-Thr6-BK from an agonist to an antagonist of BK receptors on rat ileum smooth muscle.
1. Introduction
Bradykinin (BK) is ubiquitous in mammals and its generation from precursor kininogens by
plasma/tissue kallikreins in the human kallikrein-kinin system (KKS), has been well-researched [1–3].
Currently, BK has been proved to be a critical participant associated with human physiological and
pathological processes, such as adjusting the functions of the cardiovascular, renal and nervous systems,
smooth muscle contraction, glucose metabolism, cell proliferation, inflammation and the production of
pain [3,4]. In contrast to mammalian KKS, there is no compelling evidence of the existence of KKS
among anura [5–7]. Surprisingly, following the initial discovery mammalian BK from Rana temporaria
in 1965, numerous identical BK and its structural analogues with potent smooth muscle stimulant
have been found in anuran amphibian venom apparatus-skin [7–12]. Moreover, an extraordinary
structural diversity was observed in anuran skin bradykinin-related peptides (BRPs). In addition to
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single/multiple site-substitution that frequently occurred at Arg1 and Ser6, there is some deficiency
of a certain amino-acid residue, such as the deletion of arginine at N-/C- terminus (des-Arg9 and
des-Arg1) [9,13–15]. On the other hand, hydroxylation of the proline residue often appeared among
anuran BRPs, typical example like Hyp3-BK successively isolated from three species Rana temporaria,
Phyllomedusa azurea and Hylarana guentheri [9,14,16]. In comparison of original BK, its structural
isoforms, in general, displayed N-terminal extension and/or C-terminal extension, as well as segment
insertion [9,17]. These variables regularly happened in multiples, ultimately conferring BPRs structural
diversity [9,12]. However, the reasons for their diverse expression patterns and physiological roles
of venom BK and BRPs in non-mammalian vertebrate, of the many the anuran skin BRPs, are not
clear yet.
A naturally-occurring leucine-substituted BK analogue, RVA-Leu1, Thr6-BK, also known as
amolopkinin W1, was identified in Amolops wuyiensis skin secretion and has been reported as an
antagonist in inhibiting contractility of BK on rat isolated ileum [18]. In this study, a novel BK structural
variant was identified from O. hejiangensis. It is the first BRP from the defensive skin secretion in this
frog species. This peptide primary structure, RVA-Thr6-BK, share high sequence similarity to RVA-Leu1,
Thr6-BK initially found able to antagonize the relaxant effect observed following BK application to
a rat arterial smooth muscle preparation in vitro [18]. Their corresponding chemically synthesized
replicate was subjected to our myotropic activity evaluation on rat isolated vascular and non-vascular
smooth muscles respectively.
2. Results
2.1. Molecular Cloning of Biosynthetic Precursor-Encoding cDNA and Structural Characterization of
RVA-Thr6-BK from RP-HPLC Fractions of Skin Secretion
A full-length biosynthetic BRP-precursor cDNA was consistently cloned from the cDNA library
constructed from the skin secretion of O. hejiangensis (Figure 1). Similarly, in comparison of nine known
BRP cDNA transcripts with the same length (Figure 2), this skin-kininogen precursor had 61 amino-acid
residues encoding a single 12-mer BK-like peptide following a C-terminal extension sequence VAPEIV.
The typical signal peptide consisting of 22 amino-acid residues in the translated open-reading frame
was identified through NCBI-BLAST, whereas the convertase processing site, lysine, is not the most
common. In accordance with the presence of a segment with 3 amino-acid residues (RVA) at the
N-terminal and a threonine residue at position 6 in the BK-like sequence, the novel BK-like was named
RVA-Thr6-BK. The RVA-Thr6-BK biosynthetic precursor-encoding cDNA has been deposited in the
NCBI Database (accession code; MK863068).Toxins 2019, 11, x FOR PEER REVIEW 3 of 10 
 
 
Figure 1. Nucleotide and translated open-reading frame amino-acid sequence of cDNA encoding the 
RVA-Thr6-BK precursor cloned from a skin secretion library of O. hejiangensis. The putative signal 
peptide and mature peptide are labelled by double-underlining and single-underlining, respectively. 
The asterisk indicates the stop codon. 
 
Figure 2. Amino-acid sequence alignment of RVA-Thr6-BK precursor and other BRP precursors from 
the skin secretion of several frog species. These data were obtained from GenBank and their 
corresponding accession numbers from top to bottom are CDO58214, CAR82590, ADV36199, 
SBN54116, ADM34221, ADM34238, ABF74734, ADV36198 and ADM34255, respectively. Single- and 
double-underlining represent signal and mature peptide amino-acid sequences, respectively. 
Asterisks indicate consensus residues. 
2.2. Isolation and Structural Characterization of RVA-Thr6-BK from RP-HPLC Fractions of Skin Secretion 
The average molecular mass of the putative mature peptide from the cloned precursor was 
calculated as 1400.64 Da. Thereafter, the presence of mature RVA-Thr6-BK with 12 amino-acids, was 
further confirmed by RP-HPLC isolation from within the secretion (Figure 3) and tandem mass 
spectrometry (MS/MS) fragmentation sequencing (Table 1), with the retention time of 89 min. 
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Figure 2. Amino-acid sequence alignment of RVA-Thr6-BK precursor and other BRP precursors from the
skin secretion of several frog species. These data were obtained from GenBank and their corresponding
accession numbers from top to bottom are CDO58214, CAR82590, ADV36199, SBN54116, ADM34221,
ADM34238, ABF74734, ADV36198 and ADM34255, respectively. Single- and double-underlining represent
signal and mature peptide amino-acid sequences, respectively. Asterisks indicate consensus residues.
2.2. Isolation and Structural Characterization of RVA-Thr6-BK from RP-HPLC Fractions of Skin Secretion
The average molecular mass of the putative mature peptide from the cloned precursor was calculated
as 1400.64 Da. Thereafter, the presence of mature RVA-Thr6-BK with 12 amino-acids, was further confirmed
by RP-HPLC isolation from within the secretion (Figure 3) and tandem mass spectrometry (MS/MS)
fragmentation sequencing (Table 1), with the retention time of 89 min.Toxins 2019, 11, x FOR PEER REVIEW 4 of 10 
 
 
Figure 3. Region of RP-HPLC chromatogram of O. hejiangensis skin secretion indicating the retention 
time of RVA-Thr6-BK. Absorbance wavelength was set at 214 nm. 
Table 1. Calculated singly-charged and doubly-charged b-ions and y-ions produced by MS/MS 
fragmentation of RVA-Thr6-BK identified in skin secretion. Observed ions following MS/MS 
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types of rat smooth muscle preparations (Table 2). These two peptides displayed BK-like contractile 
effects on isolated bladder preparations (rat urinary) (Figure 4A) and were found to increase the 
frequency of contraction of the uterus (Figure 4B). Moreover, at a higher concentration (10µM), RVA-
Thr6-BK caused greater contraction of bladder preparations than its leucine-substituted isoform; 
however, it required higher threshold concentration of RVA-Thr6-BK to produce a constriction 
response (Table 2 and Figure 4B). Interestingly, RVA-Thr6-BK was capable of causing potent 
contraction of rat ileum preparations, whereas, there was no significant response from rat ileum 
smooth muscle with RVA-Leu1, Thr6-BK (Figure 4C). In contrast to the contractility of the non-
vascular isolated smooth muscle of rat, both BK structural variants used here demonstrated relaxing 
action on artery preparations of the rat (Figure 4D).  
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Figure 3. Region of RP-HPLC chromatogram of O. hejiangensis skin secretion indicating the retention
time of RVA-Thr6-BK. Absorbance wavelength was set at 214 nm.
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Table 1. Calculated singly-charged and doubly-charged b-ions and y-ions produced by MS/MS
fragmentation of RVA-Thr6-BK identified in skin secretion. Observed ions following MS/MS fragmentation
are indicated in red and blue typefaces.
#1 b(1+) b(2+) b(3+) Seq. y(1+) y(2+) y(3+) #2
1 157.10840 79.05784 53.04098 R 12
2 256.17682 128.59205 86.06379 V 1244.68992 622.84860 415.56816 11
3 327.21394 164.11061 109.74283 A 1145.62150 573.31439 382.54535 10
4 483.31506 242.16117 161.77654 R 1074.58438 537.79583 358.86631 9
5 580.36783 290.68755 194.12746 P 918.48326 459.74527 306.83260 8
6 677.42060 339.21394 226.47838 P 821.43049 411.21888 274.48168 7
7 734.44207 367.72467 245.48554 G 724.37772 362.69250 242.13076 6
8 881.51049 441.25888 294.50835 F 667.35625 334.18176 223.12360 5
9 982.55817 491.78272 328.19091 T 520.28783 260.64755 174.10079 4
10 1079.61094 540.30911 360.54183 P 419.24015 210.12371 140.41823 3
11 1226.67936 613.84332 409.56464 F 322.18738 161.59733 108.06731 2
12 R 175.11896 88.06312 59.04450 1
2.3. Myotropic Activities of RVA-Thr6-BK and RVA-Leu1, Thr6-BK
Myotropic activities of RVA-Thr6-BK and RVA-Leu1, Thr6-BK were investigated in four different
types of rat smooth muscle preparations (Table 2). These two peptides displayed BK-like contractile
effects on isolated bladder preparations (rat urinary) (Figure 4A) and were found to increase the
frequency of contraction of the uterus (Figure 4B). Moreover, at a higher concentration (10 µM),
RVA-Thr6-BK caused greater contraction of bladder preparations than its leucine-substituted isoform;
however, it required higher threshold concentration of RVA-Thr6-BK to produce a constriction response
(Table 2 and Figure 4B). Interestingly, RVA-Thr6-BK was capable of causing potent contraction of
rat ileum preparations, whereas, there was no significant response from rat ileum smooth muscle
with RVA-Leu1, Thr6-BK (Figure 4C). In contrast to the contractility of the non-vascular isolated
smooth muscle of rat, both BK structural variants used here demonstrated relaxing action on artery
preparations of the rat (Figure 4D).
Table 2. Myotropic activities of RVA-Thr6-BK and RVA-Leu1, Thr6-BK in four different types of rat
smooth muscle preparations. E max indicates the maximum response of isolated tissue inducing by
BRPs at a peptide concentration of 10−5M. TC and EC50 represent threshold concentration and the
concentration of BRPs giving the half-maximal response respectively. N means undetectable value
under 10−5M of BRPs.
Isolated Tissue
E Max TC (nM) EC50 (nM)
RVA-Thr6-BK/RVA-Leu1, Thr6-BK
Bladder 0.56/0.38 (g) 100.00/10.00 7102.00/636.70
Uterus 7.00/7.00 (peaks/5 min) 10.00/100.00 817.20/3270.00
Ileum 0.43/N (g) 1.00/N 93.70/N
Tail artery −0.13/−0.08 (g) 1.00/1 8.28/30.91
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Figure 4. Dose–response curve of RVA-Thr6-BK () and RVA-Leu1, Thr6-BK (N) using (A) rat bladder
smooth muscle preparations (N = 4, n = 8), (N refers to the number of animals being study, n refers to
the number of tests conducted), (B) rat uterus smooth muscle preparations (N = 4, n = 7), (C) rat ileum
smooth muscle pre arations (N = 3, n = 4) an ( ) rat tail artery smooth muscle reparations (N = 4,
n = 8), respectively. Data indicate tension ch pared with non- eptide exposed c ntrols.
2.4. Assessment of Cytotoxic Effect on Mammalian Erythrocytes
To evaluate the potential toxicity of RVA-Thr6-BK and its analogue, RVA-Leu1, Thr6-BK, the healthy
mammalian red blood cells were treated with these two peptides (Figure 5). The results indicated that
both peptides showed no haemolytic activity in vitro.Toxins 2019, 11, x FOR PEER REVIEW 6 of 10 
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3. Discussion
Some efforts have been made in anuran amphibian skin research and conservation over several
decades [11,12,19,20]. As a consequence of these investigations, an increasing number of biologically-active
peptides (frequently anti-microorganism peptides but also neuroactive peptides and protease inhibitor
peptides) with a wide range of functions have been discovered [11,12,19–21]. Among these, it is revealed
that defensive neuroactive peptides with myotropic activity are remarkably varied in anuran skin secretions,
and these small molecule peptides can evoke contractions and relaxations on smooth muscles, BK and BRPs
being a typical example [7–9,12]. Herein, a novel BK-like peptide and its corresponding precursor-encoding
cDNA were identified. It was found that RVA-Thr6-BK precursor has a highly conserved structure
consisting of an N-terminal signal peptide domain followed by an acidic amino-acid-rich (spacer) domain
and terminating in a single mature BK-like peptide coding domain (Figure 2). This result is similar to
some of the BRP precursors in other frog species [7,14,18]. In contrast, there are only two types of BK
peptides found in human (BK and Lys0-BK). Conlon and Yano proved that there are no blood-derived
kinins in the frog plasma after treatment with trypsin [11]. Another convincing piece of evidence of no
detectable kininogens in toad plasma was that many amphibians express BK and BRPs by processing
skin-kininogens/preprobradykinins in their elaborate skin kinin system, and such a producing site differs
from that of human KKS [5]. Some identical BK derivatives found in anuran skin were also identified in
other non-mammalian vertebrate species, such as Arg0, Trp5, Leu8-BK and Thr6, Leu8-BK [21,22]. Therefore,
it has been proposed that non-mammalian vertebrates develop similar BK and BRPs for their defensive
systems, instead of having physiological roles as in mammals [7,11]. However, it is still a point of contention
whether the amphibian skin-kininogens/preprobradykinins and plasma-kininogens of humans, are indeed
expressed by homologous genes.
In this investigation, RVA-Thr6-BK was shown to have the opposite effect of RVA-Leu1, Thr6-BK
on isolated rat ileum smooth muscle in vitro, where RVA-Leu1, Thr6-BK had no direct myotropic
effects on rat ileum smooth muscle, which is consistent with our previous study [18]. Moreover,
another homologous analogue RAA-Leu1, Thr6-BK also found in Amolops wuyiensis skin secretion at
the same time was also reported as an inhibitor of BK-induced contraction of isolated rat ileum smooth
muscle [18], indicating that the Val2 amino-acid replacement is less likely to result in the alteration of
myotropic action among BRPs. The difference between of RVA-Thr6-BK and RVA-Leu1, Thr6-BK solely
involves arginine/leucine site-substitution at position 4 from the N-terminus, suggesting this is the core
site for converting RVA-Thr6-BK from an agonist to an antagonist of BK on rat ileum smooth muscle.
Besides, BK-like vasodilator action, as well as contraction effects on bladder and uterus preparations of
RVA-Leu1, Thr6-BK, are first described here. It was shown that the biological effects of BK are mediated
by specific receptors, the B1 and B2 receptors which are classified as G-protein-coupled receptors
having seven transmembrane domains crossing the lipid bilayer, three extracellular and intracellular
loops, an exposed N-terminal domain and a cytoplasmic C-terminal domain [4,23–25]. Previous
literature demonstrated that the conformation of BK was oriented randomly in aqueous environments,
but nevertheless, a specific segment in the BK sequence from residues 2–5, PPGF, was shown to have
a preference to form a β-turn conformation [26,27]. However, the unambiguous bioactive conformation
for BK binding to its receptor remains inconclusive.
In the haemolytic test, the haemoglobin release in erythrocytes was not observed in both myotropic
peptides. However, haemolytic activity in vitro is the initial test for evaluating toxic potential and this
assay is not sufficient to completely exclude these peptides with the toxicity. Further investigation
on cytotoxicity in more complex experimental models, such as cell lines [28] and insect models
(e.g., Galleria mellonella larva) [29], need to be taken into account to ensure the development of safe for
pharmaceutical use.
In summary, a novel BK analogue is described here which has not been reported previously
and this is also the first BRP isolated from O. hejiangensis. Both arginine/leucine site-substitution in
BK N-terminal extension analogues displayed similar myotropic properties to BK, except that Leu-4
site-substitution produced an antagonist of BK on the rat ileum. Our discovery and exploration
Toxins 2019, 11, 376 7 of 10
of the myotropic activities of anuran skin BRPs provide unique opportunities to better understand
the key role of venom BK and BRPs in non-mammalian vertebrates. Additionally, the structural
diversity and BK-functional-related actions suggest that anuran amphibians BRPs are unique tools for
studying structure-activity relationships as well as developing new or even more potent drugs with
therapeutic potential.
4. Materials and Methods
4.1. Skin Secretion Acquisition
Specimens of O. hejiangensis (n = 8) of undetermined sex were obtained in China and were kept in
a purpose-designed amphibian facility prior to secretion harvesting. The skin secretions were harvested
using gentle transdermal electrical stimulation initially described by Tyler and co-workers in 1992 [30].
Briefly, following stimulation by platinum electrodes (6V, 4ms pulse-width, 50 Hz, 20s duration),
the secretions from the dorsal skin of frogs were washed with deionised water, snap-frozen in liquid
nitrogen and lyophilised. The lyophilised sample was stored at −20 ◦C before analysis. This study was
performed under the UK Animal (Scientific Procedures) Act 1986, project license PPL 2694, issued by
the Department of Health, Social Services and Public Safety, Northern Ireland. The procedures had
been overseen by the IACUC of Queen’s University Belfast, and approved on 1 March 2011.
4.2. “Shotgun” Cloning of cDNA Encoding RVA-Thr6-BK Biosynthetic Precursor from Skin Secretion
Polyadenylated mRNA was extracted from 5 mg of lyophilised O. hejiangensis skin secretion
using magnetic oligo-dT beads (Dynal Biotech, Bromborough, UK) and then subjected to 3′- and
5′-RACE procedures to obtain a full-length cDNA employing a 3′-/5′-SMART-RACE kit (Clontech,
Mountain View, CA, USA) essentially as described previously [31]. Briefly, the 3′-RACE reactions
utilized a Nested Universal Primer A (NUP) (provided with the kit) and a degenerate sense
primer (S1: 5′-CCRVCNGGGTTYASSCCWTTY-3′) that was designed to a nucleotide sequence
encoding the common internal sequence of anuran skin-derived BRPs, Pro-Pro-Gly-Phe-X-Pro-Phe,
where X is either serine or threonine. Thereafter, PCR products were gel-purified, cloned using
a pGEM-T vector system (Promega Corporation, Masison, WI, USA) and sequenced using an ABI 3100
automated capillary sequencer. Accordingly, the 5′-RACE reactions employed an antisense primer
(S2: 5′-CATCAGATGACTGCCGATCCAA-3′), which was designed to a domain located within the
3′ non-translated region of the obtained 3′-RACE transcripts, and a Universal Primer A Mix (UPM)
(supplied with the kit). Similarly, 5’-RACE PCR products were gel-purified, cloned using a pGEM-T
vector system and finally sequenced.
4.3. Isolation and Structural Characterization of RVA-Thr6-BK from Skin Secretion
The isolation and structural characterization of RVA-Thr6-BK from the lyophilised O. hejiangensis
skin secretion was carried out as previous study [32]. Briefly, a Cecil CE4200 Adept (Cambridge, UK)
gradient reverse-phase High Performance Liquid Chromatography (RP-HPLC) system fitted with
a column (Phenomenex C-5, 0.46 cm × 25 cm) was employed to isolate the skin peptides from 5 mg of
lyophilise skin secretion. The fractions were collected automatically at 1 min intervals. Thereafter,
each fraction was analyzed using MALDI-TOF MS (Perseptive Biosystems, Foster City, MA, USA)
and an LCQ-Fleet electrospray ion-trap mass spectrometer (Thermo Fisher Scientific, San Jose, CA,
USA) for MS/MS fragmentation sequencing. The primary structure of the novel peptide, RVA-Thr6-BK,
was thus established.
4.4. RVA-Thr6-BK and Its Site-Substituted Analogue, RVA-Leu1, Thr6-BK: Synthesis and Purification
Here, the peptide, RVA-Leu1, Thr6-BK (RVALPPGFTPFR), was synthesized for investigating its
myotropic activity directly in comparison with that of RVA-Thr6-BK (RVARPPGFTPFR). Sufficient
quantities to detect the bioactivities of each peptide were obtained using the Tribute peptide synthesizer
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(Protein Technologies, Tucson, AZ, USA) along with standard Fmoc-chemistry according to our
previous study [32].
4.5. Myotropic Activity Evaluation on Smooth Muscles
Following asphyxiation (by CO2) and cervical dislocation, healthy female Wistar rats (250–350 g)
were dissected from the mid-ventral line and these procedures were performed as required by UK
Animal Research guidelines. After cutting the intact isolated organs into the desired sizes (10mm-length
and 5mm-width parallel muscle bundles for bladder, 5 mm-width rings for uterine horn, 5 mm-length
rings for ileum and 2 mm-width rings for tail artery), each strip hooked on tail-to-head was linked
with fine silk ligatures (0.2 mm), respectively, and mounted into 2 mL organ baths with transducers.
Meanwhile, to mimic the internal physiological environment, organ baths were filled with Kreb’s
solution at 37 ◦C flowing through the bath at 2 mL/min with constant bubbling (95% O2, 5% CO2). After
20 min of a resting period without drugs, tissues were incubated with drugs from 10−11 to 10−5 M and
the tension changes were recorded via pressure transducers with a PowerLab System (AD Instruments
Pty Ltd., Bella Vista, NSW, Australia). The retention periods for each peptide concentration were at
least 5 min.
4.6. Haemolysis Assay
Haemoglobin release in the horse erythrocytes (2% solution) (TCS Biosciences Ltd., Buckingham,
UK) were determined to evaluate the potential toxicity of RVA-Thr6-BK and its site-substituted analogue,
which was described previously [32]. The horse erythrocytes were treated with each peptide at the
intended concentrations (i.e., from 1 to 256 µM) for 2 h at 37 ◦C. 1% Triton X-100 and phosphate-buffered
saline (PBS) were served as the negative and positive controls, respectively. The supernatant of each
tube was obtained by centrifugation at 1000× g for 5 min and the OD value of supernatant was analyzed
at a wavelength of 550 nm using the plate reader.
4.7. Statistical Analysis
Data were analyzed to obtain the mean and standard error of responses by Student’s test
and dose–response curves were constructed using a best-fit algorithm through the data analysis
package Prism 6 (GraphPad Software, La Jolla, CA, USA). EC50 values were calculated from the
normalized curves.
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